
I put my daughter on fat jabs aged 11 - it wasn't a difficult decision at all and saved her from the bullies
Ashley Hamilton appeared on Monday's instalment of This Morning and revealed to Dermot O'Leary and Alison Hammond via video call from Idaho, America about why her young daughter is on the medication.
Both Ashley and her daughter Sophia have taken weight loss jabs to help them with their health.
The young girl opened up about her personal experience with her weight and bullying at school that led her to approach her mum for help.
She said: 'The bullying was definitely not ideal at all, it was just very hard to deal with because I used to think I was pretty and now I can't look at myself in the mirror without hating myself.'
Dermot asked: 'Ashley it's important to stress here because people can probably see a headline, you have always instilled exercise, you've always instilled a good diet and it was just very, very difficult to keep the weight off.
The young girl opened up about her personal experience with her weight and bullying at school that led her to approach her mum for help
'How hard was it for you to make that decision for Sophia to take the weight loss jabs?'
Ashley admitted it 'wasn't hard at all'.
She added: 'When she came to me and asked if this would work for her I told her yes, but we have to get your blood work done and your labs done to make sure there is an underlying problem, because if there was nothing showing right then that is something that we would've said, 'Okay, this is diet and exercise type of thing'.
'But it wasn't hard at all for me to decide that.'
The mother shared how she had done research on the medications and went on: 'I knew that if she needed it this is what we were going to do'.
When Sophia began to take the jabs, she soon noticed her mum had to remind her 'constantly' to eat.
'And then I started to lose weight and then I started to realise I actually had a lot of inflammation in my face and arms and in my hands... now I can wear normal sizes for my age,' she added.
Alison asked Ashley if she had received any backlash for her decision take weight loss injections herself.
She admitted: 'A lot of people deal with backlash on social media from people but for me it's actually been more in my real life, dealing with people who I can tell are judging me but it doesn't bother me it's a way for me to educate more people on what the reason is that I started.'
Sophia is no longer on the injections and during the conversation, This Morning's resident GP Dr Zoe Williams shared her take.
'The thing to consider, Sophia's a perfect example of this, Sophie already had insulin resistance and her blood work was showing that she had pre-diabetes,' Dr Zoe said.
'What you always have to consider is the risks and potential risks of a medication but weigh that against the risks and potential risks of doing nothing, when you've tried all the sensible things, the exercise, the changes to eating, the psychological approach, for some people like Sophia and her mum it's a genetic thing.
'Your genes predispose you to having problems with your weight..'
She added: 'In Sophia's case it seems it's been really helpful for her.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
16 minutes ago
- The Independent
Pharmacy warning of unsustainable demand for weight loss medication
The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'


Reuters
an hour ago
- Reuters
Roche to investigate whether new drug can delay or prevent Alzheimer's disease
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.


Reuters
2 hours ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.